Carasent Beheer

Beheer criteriumcontroles 1/4

Momenteel beschikken wij niet over voldoende informatie over de CEO.

Belangrijke informatie

Daniel Ohman

Algemeen directeur

n/a

Totale compensatie

Percentage CEO-salaris	n/a
Dienstverband CEO	2yrs
Eigendom CEO	0.2%
Management gemiddelde ambtstermijn	2yrs
Gemiddelde ambtstermijn bestuur	2.1yrs

Recente managementupdates

Recent updates

CEO

Daniel Ohman (44 yo)

2yrs

Tenure

Mr. Daniel Ohman was the Chief Executive Officer and President of GHP Specialty Care AB (publ) (formerly Global Health Partner AB (publ) since November 4, 2013 and served as its Business Area Manager of VG...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Svein Bjornstad	Chief Financial Officer	3.3yrs	geen gegevens	0.49% NOK 7.2m
Daniel Ohman	Chief Executive Officer	2yrs	geen gegevens	0.22% NOK 3.3m
Johan Eltes	Chief Technical Officer	2.1yrs	geen gegevens	geen gegevens
Jon Schultz	Legal Counsel	no data	NOK 45.00k	geen gegevens
Stefan Jernberg	Chief Compliance Officer	less than a year	geen gegevens	geen gegevens
Chris Damvakaris	Vice President of Sales & Business Development	no data	NOK 447.18k	geen gegevens
Cornelia Broqvist	Chief Marketing Officer	2.2yrs	geen gegevens	geen gegevens
Anna Larsson	People and Culture Manager	no data	geen gegevens	geen gegevens
Vilma Jonson	Head of Strategy	1.2yrs	geen gegevens	0.033% NOK 494.8k

2.0yrs

Gemiddelde duur

Ervaren management: Het managementteam van 0H9M wordt beschouwd als ervaren (gemiddelde ambtstermijn 2 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Tomas Meerits	Director	1.5yrs	geen gegevens	geen gegevens
Camilla Skoog	Independent Director	2.6yrs	geen gegevens	0.013% NOK 191.6k
Ulrika Sundling	Independent Director	2.6yrs	geen gegevens	0.028% NOK 410.0k
Petri Niemi	Independent Chairman of the Board	2.1yrs	geen gegevens	0.017% NOK 251.5k
Henric Carlsson	Independent Director	less than a year	geen gegevens	geen gegevens

2.1yrs

Gemiddelde duur

54yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van 0H9M wordt niet als ervaren beschouwd (gemiddelde ambtstermijn 2.1 jaar), wat duidt op een nieuw bestuur.

Carasent Beheer

Beheer criteriumcontroles 1/4

Belangrijke informatie

Recente managementupdates

High number of new and inexperienced directors

High number of new and inexperienced directors

Carasent ASA Announces Changes to Its Board

Independent Director recently bought kr100k worth of stock

High number of new and inexperienced directors

High number of new and inexperienced directors

Recent updates

High number of new and inexperienced directors

High number of new and inexperienced directors

Carasent ASA (OB:CARA) acquired Data - Al GmbH.

Eg Norge A/S contemplates launching a voluntary cash offer to acquire Carasent ASA (OB:CARA) for NOK 1.4 billion.

Eg Norge A/S contemplates launching a voluntary cash offer to acquire Carasent ASA (OB:CARA) for NOK 1.4 billion.

First quarter 2024 earnings released: kr0.15 loss per share (vs kr0.01 loss in 1Q 2023)

Carasent ASA Announces Changes to Its Board

Full year 2023 earnings released: kr0.60 loss per share (vs kr0.39 profit in FY 2022)

Independent Director recently bought kr100k worth of stock

Full year 2023 earnings released: kr0.64 loss per share (vs kr0.39 profit in FY 2022)

High number of new and inexperienced directors

High number of new and inexperienced directors

Carasent ASA Announces Staffan Hanstorp Resigns as A Member of the Board of Directors

Carasent ASA to Report Fiscal Year 2023 Results on Mar 22, 2024

Chief Financial Officer recently bought kr165k worth of stock

Carasent Asa Approves Dividend

Carasent Asa Approves Dividend

Independent Director recently bought kr111k worth of stock

Upcoming dividend of kr1.84 per share

Chief Executive Officer recently bought kr96k worth of stock

High number of new and inexperienced directors

Chief Executive Officer recently bought kr97k worth of stock

High number of new and inexperienced directors

Second quarter 2023 earnings released: kr0.64 loss per share (vs kr0.03 profit in 2Q 2022)

First quarter 2023 earnings released: kr0.01 loss per share (vs kr0.32 profit in 1Q 2022)

Full year 2022 earnings released: EPS: kr0.39 (vs kr0.002 loss in FY 2021)

Carasent ASA to Report Q1, 2023 Results on May 04, 2023

High number of new and inexperienced directors

Third quarter 2022 earnings released: EPS: kr0.13 (vs kr0.28 loss in 3Q 2021)

Carasent ASA (OB:CARA) acquired HPI Health Profile Institute AB for SEK 35 million.

Carasent ASA Provides Earnings Guidance for the Third Quarter and Full Year 2022

Carasent Asa Announces That Johan Lindqvist to Step Down as Chairman of the Board

Second quarter 2022 earnings released: EPS: kr0.03 (vs kr0.34 in 2Q 2021)

Investor sentiment improved over the past week

First quarter 2022 earnings released: EPS: kr0.32 (vs kr0.14 loss in 1Q 2021)

Dennis Höjer Informs that He Will Step Down as CEO of Carasent ASA

No independent directors

Full year 2021 earnings released: kr0.002 loss per share (vs kr0.85 loss in FY 2020)

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Carasent ASA (OB:CARA) completed the acquisition of Medrave Software AB.

Carasent ASA (OB:CARA) agreed to acquire Medrave Software AB for approximately SEK 130 million.

Third quarter 2021 earnings released: kr0.28 loss per share (vs kr0.21 loss in 3Q 2020)

Second quarter 2021 earnings released: EPS kr0.34 (vs kr0.14 loss in 2Q 2020)

Chief Financial Officer Lars Forsberg has left the company

Carasent ASA announced that it has received NOK 420.155987 million in funding from Cardigan Holdco S.à r.l.

Carasent ASA (OB:CARA) acquired Metodika AB for approximately SEK 110 million.

First quarter 2021 earnings released: kr0.14 loss per share (vs kr0.01 profit in 1Q 2020)

CEO

Tenure

Leiderschapsteam

Gemiddelde duur

Bestuursleden

Gemiddelde duur

Gemiddelde leeftijd